JP4887281B2 - 液体エリスロポエチン製剤 - Google Patents
液体エリスロポエチン製剤 Download PDFInfo
- Publication number
- JP4887281B2 JP4887281B2 JP2007502297A JP2007502297A JP4887281B2 JP 4887281 B2 JP4887281 B2 JP 4887281B2 JP 2007502297 A JP2007502297 A JP 2007502297A JP 2007502297 A JP2007502297 A JP 2007502297A JP 4887281 B2 JP4887281 B2 JP 4887281B2
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- erythropoietin
- preparation
- concentration
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 238000009472 formulation Methods 0.000 title claims abstract description 53
- 102000003951 Erythropoietin Human genes 0.000 title claims abstract description 37
- 108090000394 Erythropoietin Proteins 0.000 title claims abstract description 37
- 229940105423 erythropoietin Drugs 0.000 title claims abstract description 36
- 239000007788 liquid Substances 0.000 title claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims abstract description 19
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003755 preservative agent Substances 0.000 claims abstract description 11
- 239000004202 carbamide Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 32
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 229940024606 amino acid Drugs 0.000 claims description 17
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 12
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 12
- 239000004473 Threonine Substances 0.000 claims description 12
- 235000013922 glutamic acid Nutrition 0.000 claims description 12
- 239000004220 glutamic acid Substances 0.000 claims description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 12
- 229960000310 isoleucine Drugs 0.000 claims description 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 8
- 239000001110 calcium chloride Substances 0.000 claims description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 8
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 7
- 125000005907 alkyl ester group Chemical group 0.000 claims description 7
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000003204 osmotic effect Effects 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 229940068977 polysorbate 20 Drugs 0.000 claims description 4
- 239000012062 aqueous buffer Substances 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 2
- 229910001424 calcium ion Inorganic materials 0.000 claims 2
- 229940009098 aspartate Drugs 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 210000001185 bone marrow Anatomy 0.000 abstract description 5
- 210000003743 erythrocyte Anatomy 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 3
- 230000000567 anti-anemic effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 37
- 102100031939 Erythropoietin Human genes 0.000 description 37
- 239000000243 solution Substances 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000003860 storage Methods 0.000 description 10
- 229960002449 glycine Drugs 0.000 description 8
- 235000014705 isoleucine Nutrition 0.000 description 8
- 235000005772 leucine Nutrition 0.000 description 8
- 235000008729 phenylalanine Nutrition 0.000 description 8
- 235000008521 threonine Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000012669 liquid formulation Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 3
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 3
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 102000044890 human EPO Human genes 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- -1 thiol compounds Chemical class 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940070805 p-chloro-m-cresol Drugs 0.000 description 1
- 108010048732 pegylated erythropoietin Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- WZWGGYFEOBVNLA-UHFFFAOYSA-N sodium;dihydrate Chemical compound O.O.[Na] WZWGGYFEOBVNLA-UHFFFAOYSA-N 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
- Peptides Or Proteins (AREA)
Description
HSA、尿素または高分子安定化剤が存在しなくても、特定の組み合わせのアミノ酸を含有するEPO組成物は、安定性を著しく損ねることなく長期間液体形態で安定な条件下で保存可能であることが見出された。
(i)ロイシン、イソロイシン、スレオニン、グルタミン酸、アスパラギン酸、およびフェニルアラニンからなる群から選択された少なくとも4種のアミノ酸を含むことと、
(ii)保存剤、尿素、および血清タンパク質を含まないことと、
(iii)凍結乾燥物から再構成されたものではないことと
を特徴とする。
本発明の液体製剤は、免疫原性を有する可能性のある化合物を必要としない、含有する化合物の種類が全体として可能な限り少数であるといった利点だけではなく、製造工程のいずれの段階においても凍結乾燥を必要としないという利点も備えている。このことは、一方では凍結乾燥に関わる費用を節減し、他方では例えば凍結乾燥物が完全または十分に再構成できないなどの物理的問題のリスクを回避するものである。
らのアミノ酸の濃度は0.25〜1.5g/l、好ましくは0.5〜1.25g/lの範囲にあり、特に好ましくは1.0g/lである。
7.4であり、特に好ましくは7.0〜7.4である。所望のpH範囲を達成するために調整を要する場合は、適切な溶液を用いて、すなわちpH値を低下させる必要がある場合は酸性溶液、pH値を上昇させる必要がある場合はアルカリ性溶液を用いて、pH値を調整する。それぞれHClおよびNaOHを用いてpH値を調整することが好ましい。
使用される緩衝剤は、注射溶液または輸液を上記に特定したpH範囲にするのに必要な濃度で緩衝作用を示すことのできる、任意の生理学的に許容可能な緩衝剤であってよい。適切な緩衝剤は、例えば、リン酸塩、クエン酸塩、炭酸塩、およびHEPESである。リン酸緩衝剤を使用することが好ましい。緩衝剤化合物は、約20〜100mM、好ましくは30〜80mM、特に好ましくは40〜60mMの濃度で使用される。
本発明の好適な実施形態では、活性物質であるEPOに加えてアミノ酸であるロイシン、イソロイシン、スレオニン、グルタミン酸、フェニルアラニン、およびグリシン、ならびに塩化カルシウム、ポリソルベート、リン酸緩衝剤および塩化ナトリウムを含有し、その他の含有成分が存在しないことを特徴とする液体EPO製剤が提供される。
eoRecormon(登録商標)およびErypo(登録商標)を参照されたい。
本発明の製剤の製造は、先行技術における慣用法により実施可能である。
最後に、完成した液体製剤を適切な容器に詰める。該液体製剤は施用時まで同容器内で保存される。前記容器は、特に、シリンジ製品、穿刺式の密栓フラスコ、またはアンプルである。
濃度が3,333IE/mlの液体エリスロポエチン製剤の調製。
エリスロポエチンの含量を除き、シリンジ製品あたりの個々の成分の含量は実施例1に記載の含量に相当する。本実施例の場合、エリスロポエチンの含量は10,000IE/mlである。
例えばタンパク質含量が1,000μg/mlで活性がタンパク質1mgあたり130,000IEである例示的な1リットルの設定容量では、以下の表に示した組成となる(活性成分のバルクの密度を1.008g/lと仮定)。
トリウム二水和物、塩化ナトリウムおよび水を含有する薬剤溶液が調製されるが、その組成は秤量すべき個々の成分の量を計算する際に考慮されている。
注射用水の80%をセットアップ容器に用意する。水の温度を測定し、25℃未満にしておかなければならない。続いて、上述の組成に対応するように秤量されたリン酸二水素
ナトリウム二水和物、リン酸一水素二ナトリウム二水和物、塩化カルシウム、グリシン、ロイシン、イソロイシン、スレオニン、グルタミン酸、フェニルアラニン、および塩化ナトリウムを、窒素による保護下で撹拌しながら慎重に添加する。この溶液を、全ての成分が完全に溶解して均質な溶液が形成されるまで、ただし少なくとも15分間撹拌する。続いて、別途注射用水溶液として調製したポリソルベート20をセットアップ容器に添加する。この溶液を少なくとも15分間撹拌する。
再度、調製物の温度(18〜25℃に設定)およびpH値を確認する。pH値が7.4を超えているかまたは7.0未満である場合は、それぞれ0.1Nの塩酸および0.1Nの水酸化ナトリウム溶液を用いて調整する。
本発明のEPO製剤の長期安定性を、BRP標準品を基準として比較することにより確認した。この試験は、EPO溶液を保存すると分解反応および副反応が生じ、該反応により、とりわけメチオニンおよびシステインの側鎖の酸化が引き起こされるという事実に基づくものである。EPOのMet45は、酸化されてスルホキシドを形成することが特に多い。前記メチオニンスルホキシドは、トリプシンを用いてEPOをタンパク質分解した後にRP‐HPLC分析することによって検出可能である。本実施例では、酸化されたメチオニンの割合が保存安定性の指標である。すなわち、この割合が高いほど保存安定性が低いことになる。種々の保存温度(2〜8℃、25℃、40℃)および種々の保存期間(6週間、12週間、6ヶ月)における本発明の製剤中のメチオニン酸化型分子種の割合を、従来技術の製剤と比較して測定した結果、本発明の製剤は従来技術の液体製剤に匹敵する安定性を有することが示された。
Claims (20)
- 安定な液体エリスロポエチン製剤であって、
(i)少なくともロイシン、イソロイシン、スレオニン、グルタミン酸、およびフェニルアラニンを含有し、
(ii)保存剤、尿素およびヒト血清アルブミンを含有せず、
(iii)凍結乾燥物から再構成されたものではない
ことを特徴とする製剤。 - グリシンをさらに含有することを特徴とする請求項1に記載の製剤。
- 非イオン性の界面活性剤をさらに含んでなることを特徴とする請求項1または2に記載の製剤。
- 界面活性剤はポリオキシエチレンソルビタンアルキルエステルである、請求項3に記載の製剤。
- ポリオキシエチレンソルビタンアルキルエステルはポリソルベート20またはポリソルベート80である、請求項4に記載の製剤。
- 浸透圧が250ミリオスモル/kg〜300ミリオスモル/kgの範囲内にあることを特徴とする請求項1〜5のいずれか一項に記載の製剤。
- 浸透圧が塩化ナトリウムで調整されることを特徴とする請求項6に記載の製剤。
- 生理学的に許容可能な緩衝剤をさらに含んでなることを特徴とする請求項1〜7のいずれか一項に記載の製剤。
- 緩衝剤はリン酸緩衝剤である、請求項8に記載の製剤。
- pHが7.0〜7.4の範囲内にあることを特徴とする請求項1〜9のいずれか一項に記載の製剤。
- カルシウムイオンをさらに含んでなる、請求項1〜10のいずれか一項に記載の製剤。
- カルシウムイオンは塩化カルシウムに由来することを特徴とする請求項11に記載の製剤。
- 塩化カルシウム、ポリソルベート、リン酸緩衝剤および塩化ナトリウムをさらに含有する請求項2に記載の製剤。
- イソロイシンおよびロイシンの濃度がそれぞれ0.25〜1.5g/lの範囲内にあることを特徴とする請求項1〜13のいずれか一項に記載の製剤。
- アスパラギン酸が含まれる場合、グルタミン酸およびアスパラギン酸の濃度が0.1〜0.5g/lの範囲内にあることを特徴とする請求項1〜14のいずれか一項に記載の製剤。
- スレオニン濃度が0.1〜0.5g/lの範囲内にあることを特徴とする請求項1〜15のいずれか一項に記載の製剤。
- フェニルアラニン濃度が0.2〜1.0g/lの範囲内にあることを特徴とする請求項1〜16のいずれか一項に記載の製剤。
- グリシンが含まれる場合、グリシン濃度が2.0〜10.0g/lの範囲内にあることを特徴とする請求項2〜17のいずれか一項に記載の製剤。
- 保存上安定な液体エリスロポエチン製剤を調製する方法であって、エリスロポエチン、アミノ酸であるロイシン、イソロイシン、スレオニン、グルタミン酸、フェニルアラニン、およびグリシン、ならびに塩化カルシウム、ポリオキシエチレンソルビタンアルキルエステル、塩化ナトリウムを水性緩衝液に溶解する工程を含んでなり、該方法のいずれの段階においても製剤が凍結乾燥されないことと、該製剤が尿素を含まないこととを特徴とする方法。
- 成分が以下の順序、すなわち
(a)塩化カルシウム、
(b)塩化ナトリウム、
(c)ロイシン、イソロイシン、スレオニン、グルタミン酸、フェニルアラニン、およびグリシン、
(d)ポリオキシエチレンソルビタンアルキルエステル、および
(e)エリスロポエチン
の順に溶解されることを特徴とする請求項19に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004011663A DE102004011663B4 (de) | 2004-03-10 | 2004-03-10 | Erythropoietin-Flüssigformulierung |
DE102004011663.6 | 2004-03-10 | ||
PCT/EP2005/002551 WO2005087804A1 (de) | 2004-03-10 | 2005-03-10 | Erythropoietin-flüssigformulierung |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007536215A JP2007536215A (ja) | 2007-12-13 |
JP4887281B2 true JP4887281B2 (ja) | 2012-02-29 |
Family
ID=34895145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007502297A Active JP4887281B2 (ja) | 2004-03-10 | 2005-03-10 | 液体エリスロポエチン製剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7767644B2 (ja) |
EP (2) | EP1723172B1 (ja) |
JP (1) | JP4887281B2 (ja) |
AT (2) | ATE369382T1 (ja) |
CA (1) | CA2558985C (ja) |
CY (1) | CY1106954T1 (ja) |
DE (4) | DE102004011663B4 (ja) |
DK (1) | DK1723172T3 (ja) |
ES (1) | ES2292103T3 (ja) |
PL (1) | PL1723172T3 (ja) |
PT (1) | PT1723172E (ja) |
SI (1) | SI1723172T1 (ja) |
WO (1) | WO2005087804A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE049023T2 (hu) * | 2008-08-15 | 2020-08-28 | Ironwood Pharmaceuticals Inc | Linaklotidot tartalmazó, szájon át történõ beadásra szolgáló készítmények |
WO2011017502A2 (en) * | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Linaclotide-containing formulations for oral administration |
UA108636C2 (xx) | 2010-02-17 | 2015-05-25 | Пептид | |
RS59978B1 (sr) | 2010-08-11 | 2020-03-31 | Ironwood Pharmaceuticals Inc | Stabilne formulacije linaklotida |
DK2776055T3 (en) | 2011-08-17 | 2017-03-06 | Ironwood Pharmaceuticals Inc | TREATMENTS FOR GASTROINTESTINAL DISORDERS |
KR101759694B1 (ko) | 2011-10-28 | 2017-07-19 | 인테그리티 바이오, 아이엔씨. | 아미노산을 함유하는 단백질 제제 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6471818A (en) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Storage-stable and tolerable human protein medicine and manufacture |
JPH10182481A (ja) * | 1996-04-26 | 1998-07-07 | Chugai Pharmaceut Co Ltd | エリスロポエチン溶液製剤 |
WO2000051629A1 (fr) * | 1999-03-01 | 2000-09-08 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a longue conservation |
JP2002541208A (ja) * | 1999-04-09 | 2002-12-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | エリトロポイエチンの薬剤組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6197229A (ja) | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
US20030162711A1 (en) * | 1996-04-24 | 2003-08-28 | Soren Bjorn | Pharmaceutical formulation |
DE19856443A1 (de) | 1998-12-08 | 2000-06-21 | Centeon Pharma Gmbh | Stabilisiertes Antithrombin III-Präparat |
JP2003520777A (ja) * | 1999-07-22 | 2003-07-08 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 防腐医薬製剤 |
EP1525889A1 (en) * | 2000-05-15 | 2005-04-27 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivative |
US20040022792A1 (en) * | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
-
2004
- 2004-03-10 DE DE102004011663A patent/DE102004011663B4/de not_active Expired - Fee Related
- 2004-03-10 DE DE202004020676U patent/DE202004020676U1/de not_active Expired - Lifetime
-
2005
- 2005-03-10 AT AT05707735T patent/ATE369382T1/de active
- 2005-03-10 US US10/592,241 patent/US7767644B2/en active Active
- 2005-03-10 DE DE502005010276T patent/DE502005010276D1/de active Active
- 2005-03-10 ES ES05707735T patent/ES2292103T3/es active Active
- 2005-03-10 PL PL05707735T patent/PL1723172T3/pl unknown
- 2005-03-10 JP JP2007502297A patent/JP4887281B2/ja active Active
- 2005-03-10 DE DE502005001187T patent/DE502005001187D1/de active Active
- 2005-03-10 AT AT07106020T patent/ATE481419T1/de active
- 2005-03-10 EP EP05707735A patent/EP1723172B1/de active Active
- 2005-03-10 PT PT05707735T patent/PT1723172E/pt unknown
- 2005-03-10 SI SI200530045T patent/SI1723172T1/sl unknown
- 2005-03-10 WO PCT/EP2005/002551 patent/WO2005087804A1/de active IP Right Grant
- 2005-03-10 CA CA2558985A patent/CA2558985C/en active Active
- 2005-03-10 EP EP07106020A patent/EP1806361B1/de not_active Not-in-force
- 2005-03-10 DK DK05707735T patent/DK1723172T3/da active
-
2007
- 2007-10-24 CY CY20071101365T patent/CY1106954T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6471818A (en) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Storage-stable and tolerable human protein medicine and manufacture |
JPH10182481A (ja) * | 1996-04-26 | 1998-07-07 | Chugai Pharmaceut Co Ltd | エリスロポエチン溶液製剤 |
WO2000051629A1 (fr) * | 1999-03-01 | 2000-09-08 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a longue conservation |
JP2002541208A (ja) * | 1999-04-09 | 2002-12-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | エリトロポイエチンの薬剤組成物 |
Also Published As
Publication number | Publication date |
---|---|
DE202004020676U1 (de) | 2005-11-10 |
US20080039371A1 (en) | 2008-02-14 |
DE502005010276D1 (de) | 2010-10-28 |
DE102004011663A1 (de) | 2005-09-29 |
US7767644B2 (en) | 2010-08-03 |
CA2558985A1 (en) | 2005-09-22 |
EP1723172A1 (de) | 2006-11-22 |
CA2558985C (en) | 2012-09-25 |
DE102004011663B4 (de) | 2006-04-27 |
WO2005087804A1 (de) | 2005-09-22 |
CY1106954T1 (el) | 2012-09-26 |
PT1723172E (pt) | 2007-10-29 |
DE502005001187D1 (de) | 2007-09-20 |
ATE369382T1 (de) | 2007-08-15 |
ES2292103T3 (es) | 2008-03-01 |
EP1806361B1 (de) | 2010-09-15 |
EP1806361A1 (de) | 2007-07-11 |
ATE481419T1 (de) | 2010-10-15 |
EP1723172B1 (de) | 2007-08-08 |
DK1723172T3 (da) | 2007-12-27 |
SI1723172T1 (sl) | 2007-12-31 |
PL1723172T3 (pl) | 2007-12-31 |
JP2007536215A (ja) | 2007-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6174856B1 (en) | Stabilized insulin compositions | |
RU2100032C1 (ru) | Фармацевтическая композиция, регулирующая гематопоэз | |
EP1180368B1 (en) | Freeze dried hgf preparations | |
JP4887281B2 (ja) | 液体エリスロポエチン製剤 | |
PT1397155E (pt) | Formulação de libertação sustentada | |
IE61340B1 (en) | Stable interferon complexes | |
WO2002011753A1 (fr) | Preparations proteiniques a injecter | |
JP2015527350A (ja) | 第viii因子の液体製剤 | |
EP1641486B1 (en) | Stable, aqueous solution of human erythropoietin, not containing serum albumin | |
EP0612530B1 (en) | Pharmaceutical preparations containing tumor cytotoxic factor | |
US7192926B2 (en) | Use of recombinant gelatin-like proteins as plasma expanders and compositions suitable for plasma substitution | |
EA006220B1 (ru) | Многодозовые эритропоэтиновые составы | |
CA2545880C (en) | Erythropoietin solution formulation | |
US20160095904A1 (en) | Stabilized liquid formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100518 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100806 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110318 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110930 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111115 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111212 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141216 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4887281 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |